Dr Reddys Laboratories Ltd's Q3FY25 Quarter Results
- 24 Jan 2025
Result Summary
- Dr Reddys Laboratories Ltd reported a 2.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 14.5%.
- Its expenses for the quarter were up by 3.5% QoQ and 18.4% YoY.
- The net profit increased 4.6% QoQ and increased 1.7% YoY.
- The earnings per share (EPS) of Dr Reddys Laboratories Ltd stood at 16.9 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 8531.40 | 8345.70 | 7453.00 | 2.2% | 14.5% |
Total Expenses | 6661.30 | 6434.40 | 5626.60 | 3.5% | 18.4% |
Profit Before Tax | 1870.10 | 1911.30 | 1826.40 | -2.2% | 2.4% |
Tax | 470.10 | 575.50 | 448.20 | -18.3% | 4.9% |
Profit After Tax | 1404.20 | 1341.90 | 1380.90 | 4.6% | 1.7% |
Earnings Per Share | 16.90 | 80.50 | 82.80 | -79.0% | -79.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Dr Reddys Laboratories Ltd is a prominent pharmaceutical company based in India. It operates in the healthcare industry, primarily involved in the manufacturing and marketing of a wide range of pharmaceutical products and services. The company is known for its generic drug formulations, active pharmaceutical ingredients (APIs), and proprietary products. Dr Reddys Laboratories has a significant presence in both domestic and international markets, with a focus on research and development to drive innovation in its product offerings. No recent major developments are available from the current dataset.
Revenue
For the third quarter of the fiscal year 2025 (Q3FY25), Dr Reddys Laboratories Ltd reported a total income of ₹8531.40 crores. This represents a quarter-over-quarter (QoQ) increase of 2.2% from the previous quarter (Q2FY25), where the total income was ₹8345.70 crores. On a year-over-year (YoY) basis, there has been a substantial increase of 14.5% compared to the total income of ₹7453.00 crores in the same quarter of the previous fiscal year (Q3FY24). The growth in revenue highlights the company's ability to generate higher sales compared to both the previous quarter and the same period last year.
Profitability
During Q3FY25, the company reported a profit before tax (PBT) of ₹1870.10 crores, demonstrating a slight decrease of 2.2% QoQ from ₹1911.30 crores in Q2FY25. However, when compared to Q3FY24, PBT shows a modest increase of 2.4% from ₹1826.40 crores. The tax expense in Q3FY25 was ₹470.10 crores, marking a significant reduction of 18.3% QoQ and an increase of 4.9% YoY from ₹448.20 crores in Q3FY24. Profit after tax (PAT) for Q3FY25 was ₹1404.20 crores, which is an increase of 4.6% QoQ and 1.7% YoY from ₹1380.90 crores in Q3FY24. These figures indicate stable profitability with slight variations compared to previous periods.
Operating Metrics
The earnings per share (EPS) for Dr Reddys Laboratories Ltd in Q3FY25 was ₹16.90, showing a significant decline of 79.0% QoQ from ₹80.50 in Q2FY25 and a decrease of 79.6% YoY from ₹82.80 in Q3FY24. This decline in EPS is noteworthy, indicating a change in earnings attributable to shareholders. Total expenses for the quarter were ₹6661.30 crores, up by 3.5% QoQ from ₹6434.40 crores and 18.4% YoY from ₹5626.60 crores in Q3FY24. The increase in expenses aligns with the revenue growth but reflects on the operational efficiency of the company within the period analyzed.
